Breast Cancer Research and Treatment

, Volume 124, Issue 3, pp 793–800 | Cite as

Recording of hormone therapy and breast density in breast screening programs: summary and recommendations of the International Cancer Screening Network

  • Brian Cox
  • Rachel Ballard-Barbash
  • Mireille Broeders
  • Emily Dowling
  • Nea Malila
  • Rene Shumak
  • Stephen Taplin
  • Diana Buist
  • Diana Miglioretti


Breast density and the use of hormone therapy (HT) for menopausal symptoms alter the risk of breast cancer and both factors influence screening mammography performance. The International Cancer Screening Network (ICSN) surveyed its 29 member countries and found that few programs record breast density or the use of HT among screening participants. This may affect the ability of programs to assess their effectiveness in reducing breast cancer mortality. Seven countries recorded the use of HT at screening, and some were able to link screening records to individual prescribing records of HT. Eight countries reported recording breast density at screening mammography for some or all women screened. The recommendations of the ICSN for recording information about breast density and HT are presented.


Breast screening Breast density Hormone therapy Program monitoring 



We gratefully acknowledge the following members of the International Cancer Screening Network who provided information about their screening programs: Julianne Quaine (Australia), Ronaldo Silva Correa (Brazil), Jay Onysko (Canada), Adam Svoboknik (Czech Republic), Elsebeth Lynge (Denmark), Dominik Deitz (Germany), Gad Rennert (Israel), Noriaki Hiroshi (Japan), Won Chul Lee (Korea), Jacques Fracheboud (Netherlands), Solveig Hofvind (Norway), Jean-Luc Bulliard (Switzerland), Sue Moss (United Kingdom), Rod Walker (United States), and Gonzalo Pou (Uruguay). We also thank Gretchen Keel at Information Management Systems, Inc. for her programing support for the development and synopsis of the web survey, and Kathy Sedgwick at NOVA Research Company for her logistical support for the working group. Brian Cox was supported by the Director’s Cancer Research Trust. We also acknowledge funding support for this project from the National Cancer Institute, National Institutes of Health, United States. This study was partially supported by the National Cancer Institute Breast Cancer Surveillance Consortium (BCSC) (U01CA63740, U01CA86076, U01CA86082, U01CA63736, U01CA70013, U01CA69976, U01CA63731, U01CA70040).

Conflicts of interest



  1. 1.
    Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333CrossRefGoogle Scholar
  2. 2.
    Beral V, Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362(9382):419–427CrossRefPubMedGoogle Scholar
  3. 3.
    Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53297 women with breast cancer and 100239 women without breast cancer from 54 epidemiological studies. Lancet 347(9017):1713–1727CrossRefGoogle Scholar
  4. 4.
    Reeves GK, Beral V, Green J, Gathani T, Bull D, Million Women Study Collaborators (2006) Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol 7(11):910–918CrossRefPubMedGoogle Scholar
  5. 5.
    Gertig DM, Erbas B, Fletcher A, Amos A, Kavanagh AM (2003) Duration of hormone replacement therapy, breast tumour size and grade in a screening programme. Breast Cancer Res Treat 80(3):267–273CrossRefPubMedGoogle Scholar
  6. 6.
    Daling JR, Malone KE, Doody DR, Voigt LF, Bernstein L, Marchbanks PA et al (2003) Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50–64 years. Cancer Epidemiol Biomarkers Prev 12(11 II):1175–1181PubMedGoogle Scholar
  7. 7.
    Gayet A, Esteve J, Seradour B, Piana L, Jacquemier J (2003) Does hormone replacement therapy increase the frequency of breast atypical hyperplasia in postmenopausal women? Results from the Bouches du Rhone district screening campaign. Eur J Cancer 39(12):1738–1745CrossRefPubMedGoogle Scholar
  8. 8.
    Shapiro S, Coleman EA, Broeders M, Codd M, De Koning H, Fracheboud J et al (1998) Breast cancer screening programmes in 22 countries: current policies, administration and guidelines. Int J Epidemiol 27(5):735–742CrossRefPubMedGoogle Scholar
  9. 9.
    Ballard-Barbash R, Klabunde C, Paci E, Broeders M, Coleman EA, Fracheboud J et al (1999) Breast cancer screening in 21 countries: delivery of services, notification of results and outcomes ascertainment. Eur J Cancer Prev 8(5):417–426CrossRefPubMedGoogle Scholar
  10. 10.
    Klabunde C, Bouchard F, Taplin S, Scharpantgen A, Ballard-Barbash R (2001) Quality assurance for screening mammography: an international comparison. J Epidemiol Community Health 55(3):204–212CrossRefPubMedGoogle Scholar
  11. 11.
    Klabunde CN, Sancho-Garnier H, Broeders M, Thoresen S, Rodrigues VJL, Ballard-Barbash R (2001) Quality assurance for screening mammography data collection systems in 22 countries. Int J Technol Assess Health Care 17(4):528–541PubMedGoogle Scholar
  12. 12.
    Hendrick RE, Klabunde C, Grivegnee A, Gonzalo POU, Ballard-Barbash R (2002) Technical quality control practices in mammography screening programs in 22 countries. Int J Qual Health Care 14(3):219–226PubMedGoogle Scholar
  13. 13.
    Klabunde CN, Sancho-Garnier H, Taplin S, Thoresen S, Ohuchi N, Ballard-Barbash R et al (2002) Quality assurance in follow-up and initial treatment for screening mammography programs in 22 countries. Int J Qual Health Care 14(6):449–461CrossRefPubMedGoogle Scholar
  14. 14.
    Yankaskas BC, Klabunde CN, Ancelle-Park R, Rennert G, Wang H, Fracheboud J et al (2004) International comparison of performance measures for screening mammography: can it be done? J Med Screen 11(4):187–193CrossRefPubMedGoogle Scholar
  15. 15.
    Bulliard J-L, Sasieni P, Klabunde C, De Landtsheer J-P, Yankaskas B, Fracheboud J (2006) Methodological issues in international comparison of interval breast cancers. Int J Cancer 119:1158–1163CrossRefPubMedGoogle Scholar
  16. 16.
    Geller BM, Zapka J, Hofvind SSH, Scharpantgen A, Giordano L, Ohuchi N et al (2007) Communicating with women about mammography. J Cancer Educ 22(1):25–31CrossRefPubMedGoogle Scholar
  17. 17.
    Klabunde CN, Ballard-Barbash R (2007) Evaluating population-based screening mammography programs internationally. Semin Breast Dis 10(2):102–107CrossRefPubMedGoogle Scholar
  18. 18.
    Wolfe JN (1978) Risk for breast cancer development determined by mammographic parenchymal pattern. Cancer 37:2486–2492CrossRefGoogle Scholar
  19. 19.
    Gram IT, Funkhouser E, Tabar L (1997) The Tabar classification of mammographic parenchymal patterns. Eur J Radiol 24:131–136CrossRefPubMedGoogle Scholar
  20. 20.
    American College of Radiology (2003) American College of Radiology (ACR) Breast Imaging Reporting and Data System Atlas (BI-RADS® Atlas). American College of Radiology, Reston, VAGoogle Scholar
  21. 21.
    Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350(9084):1047–1059CrossRefGoogle Scholar
  22. 22.
    Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian JZ (1999) Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 130(7):545–553PubMedGoogle Scholar
  23. 23.
    Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack MM, Flanders WD et al (1991) A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 265(15):1985–1990CrossRefPubMedGoogle Scholar
  24. 24.
    Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B et al (1992) Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 117(12):1016–1037PubMedGoogle Scholar
  25. 25.
    Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M et al (2009) Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 360(6):573–587CrossRefPubMedGoogle Scholar
  26. 26.
    Kerlikowske K, Miglioretti DL, Buist DSM, Walker R, Carney PA, National Cancer Institute-Sponsored Breast Cancer Surveillance Consortium (2007) Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst 99(17):1335–1339CrossRefPubMedGoogle Scholar
  27. 27.
    Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ et al (2007) The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356(16):1670–1674CrossRefPubMedGoogle Scholar
  28. 28.
    Kumle M (2008) Declining breast cancer incidence and decreased HRT use. Lancet 372(9639):608–610CrossRefPubMedGoogle Scholar
  29. 29.
    Canfell K, Banks E, Moa AM, Beral V (2008) Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust 188(11):641–644PubMedGoogle Scholar
  30. 30.
    Clarke CA, Glaser SL (2007) Declines in breast cancer after the WHI: apparent impact of hormone therapy. Cancer Causes Control 18(8):847–852CrossRefPubMedGoogle Scholar
  31. 31.
    Verkooijen HM, Koot VCM, Fioretta G, Van Der Heiden M, Schipper MEI, Rapiti E et al (2008) Hormone replacement therapy, mammography screening and changing age-specific incidence rates of breast cancer: an ecological study comparing two European populations. Breast Cancer Res Treat 107(3):389–395CrossRefPubMedGoogle Scholar
  32. 32.
    Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ (1998) Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev 7(12):1133–1144PubMedGoogle Scholar
  33. 33.
    Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C et al (2003) Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 95(16):1218–1226CrossRefPubMedGoogle Scholar
  34. 34.
    Warren R (2004) Hormones and mammographic breast density. Maturitas 49(1):67–78CrossRefPubMedGoogle Scholar
  35. 35.
    Greendale GA, Reboussin BA, Sie A et al (1999) Effects of estrogen and estrogen–progestin on mammographic parenchymal density. Ann Intern Med 130:262–269Google Scholar
  36. 36.
    Myles JP, Salmininen T, Duffy SW, Prevost TC, Day NE, Hakama M (2004) Prospective estimation of rates of change in mammographic parenchymal patterns: influence of age and of hormone replacement therapy. Breast 13(1):56–60CrossRefPubMedGoogle Scholar
  37. 37.
    Wang H, Bjurstam N, Bjorndal H, Braaten A, Eriksen L, Skaane P et al (2001) Interval cancers in the Norwegian breast cancer screening program: frequency, characteristics and use of HRT. Int J Cancer 94(4):594–598CrossRefPubMedGoogle Scholar
  38. 38.
    Chiarelli AM, Kirsh VA, Klar NS, Shumak R, Jong R, Fishell E et al (2006) Influence of patterns of hormone replacement therapy use and mammographic density on breast cancer detection. Cancer Epidemiol Biomarkers Prev 15(10):1856–1862CrossRefPubMedGoogle Scholar
  39. 39.
    Takata Y, Maskerinec G, Le Marchand L (2007) Breast density and polymorphisms in genes coding for CYPIA2 and COMT: the multiethnic cohort. BMC Cancer 7.
  40. 40.
    Maskarinec G, Takata Y, Pagano I, Lurie G, Wilkens LR, Kolonel LN (2006) Alcohol consumption and mammographic density in a multiethnic population. Int J Cancer 118(10):2579–2583CrossRefPubMedGoogle Scholar
  41. 41.
    Turashvili G, McKinney S, Martin L, Gelmon KA, Watson P, Boyd N et al (2008) Columnar cell lesions, mammographic density and breast cancer risk. Breast Cancer Res Treat 115:561–571CrossRefPubMedGoogle Scholar
  42. 42.
    Warner E, Lockwood G, Tritchler D, Boyd NF (1992) The risk of breast cancer associated with mammographic parenchymal patterns: a meta-analysis of the published literature to examine the effect of method of classification. Cancer Detect Prev 16(1):67–72PubMedGoogle Scholar
  43. 43.
    Byng JW, Boyd NF, Fishell E, Jong RA, Yaffe MJ (1994) The quantitative analysis of mammographic densities. Phys Med Biol 39(10):1629–1638CrossRefPubMedGoogle Scholar
  44. 44.
    Gram IT, Bremnes Y, Ursin G, Maskarinec G, Bjurstam N, Lund E (2005) Percentage density, Wolfe’s and Tabar’s mammographic patterns: agreement and association with risk factors for breast cancer. Breast Cancer Res 7:R854–R861CrossRefPubMedGoogle Scholar
  45. 45.
    Yaffe MJ (2008) Mammographic density: measurement of mammographic density. Breast Cancer Res 10(3):209CrossRefPubMedGoogle Scholar
  46. 46.
    Heine JJ, Carston MJ, Scott CG, Brandt KR, Wu FF, Pankratz VS et al (2008) An automated approach for estimation of breast density. Cancer Epidemiol Biomarkers Prev 17(11):3090–3097CrossRefPubMedGoogle Scholar
  47. 47.
    Carney PA, Miglioretti DL, Yankaskas BC, Kerlikowske K, Rosenberg R, Rutter CM et al (2003) Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 138(3):168–175PubMedGoogle Scholar
  48. 48.
    Kavanagh AM, Cawson J, Byrnes GB, Giles GG, Marr G, Tong B et al (2005) Hormone replacement therapy, percent mammographic density, and sensitivity of mammography. Cancer Epidemiol Biomarkers Prev 14(5):1060–1064CrossRefPubMedGoogle Scholar
  49. 49.
    Vernet MDM, Checa MA, Macia F, Casamitjana M, Carreras R (2006) Influence of hormone replacement therapy on the accuracy of screening mammography. Breast J 12(2):154–158CrossRefGoogle Scholar
  50. 50.
    Marias K, Behrenbruch C, Highnam R, Parbhoo S, Seifalian A, Brady M (2004) A mammographic image analysis method to detect and measure changes in breast density. Eur J Radiol 52(3):276–282CrossRefPubMedGoogle Scholar
  51. 51.
    Kerlikowske K, Ichikawa L, Miglioretti DL, Buist DSM, Vacek PM, Smith-Bindman R et al (2007) Longitudinal measurement of clinical mammographic breast density to improve estimation of breast cancer risk. J Natl Cancer Inst 99(5):386–395CrossRefPubMedGoogle Scholar
  52. 52.
    Rosenberg RD, Hunt WC, Williamson MR, Gilliland FD, Wiest PW, Kelsey CA et al (1998) Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: review of 183, 134 screening mammograms in Albuquerque, New Mexico. Radiology 209(2):511–518PubMedGoogle Scholar
  53. 53.
    Carney PA, Kasales CJ, Tosteson ANA, Weiss JE, Goodrich ME, Poplack SP et al (2004) Likelihood of additional work-up among women undergoing routine screening mammography: the impact of age, breast density, and hormone therapy use. Prev Med 39(1):48–55CrossRefPubMedGoogle Scholar
  54. 54.
    Banks E, Reeves G, Beral V, Bull D, Crossley B, Simmonds M et al (2006) Hormone replacement therapy and false positive recall in the Million Women Study: patterns of use, hormonal constituents and consistency of effect. Breast Cancer Res 8(1):R8Google Scholar
  55. 55.
    Crouchley K, Wylie E, Khong E (2006) Hormone replacement therapy and mammographic screening outcomes in Western Australia. J Med Screen 13(2):93–97CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Brian Cox
    • 1
  • Rachel Ballard-Barbash
    • 2
  • Mireille Broeders
    • 3
  • Emily Dowling
    • 2
  • Nea Malila
    • 4
    • 5
  • Rene Shumak
    • 6
  • Stephen Taplin
    • 2
  • Diana Buist
    • 7
  • Diana Miglioretti
    • 7
  1. 1.Hugh Adam Cancer Epidemiology Unit, Department of Preventive and Social Medicine, Dunedin School of MedicineUniversity of OtagoDunedinNew Zealand
  2. 2.Applied Research Program, Division of Cancer Control and Population SciencesNational Cancer InstituteBethesdaUSA
  3. 3.Department of Epidemiology, Biostatistics and Health Technology AssessmentRadboud University Nijmegen Medical CentreNijmegenThe Netherlands
  4. 4.Mass Screening Registry, Finnish Cancer RegistryHelsinkiFinland
  5. 5.Tampere School of Public HealthUniversity of TampereTampereFinland
  6. 6.Ontario Breast Screening Program, Cancer Care OntarioTorontoCanada
  7. 7.Group Health Research InstituteSeattleUSA

Personalised recommendations